CLINICAL TRIALS PROFILE FOR RINVOQ LQ

All Clinical Trials for RINVOQ LQ

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02049138 ↗	An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects	Completed	AbbVie	Phase 2	2014-01-24	This is a Phase 2, multicenter, open-label extension study in RA subjects. The sub-study is to assess the impact of upadacitinib treatment (15 mg QD and 30 mg QD) with background MTX on immunological responses to Prevnar 13® in RA patients.
NCT02675426 ↗	A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone	Active, not recruiting	AbbVie	Phase 3	2015-12-17	The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to severely active rheumatoid arthritis who were on a stable dose of csDMARDs and had an inadequate response to csDMARDs.
NCT02706847 ↗	A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs	Active, not recruiting	AbbVie	Phase 3	2016-03-15	The study objective of Period 1 (Day 1 to Week 24) is to compare the safety and efficacy of 30 mg once daily (QD) and 15 mg QD upadacitinib versus placebo for the treatment of signs and symptoms of participants with moderately to severely active RA who were on a stable dose of csDMARDs and had an inadequate response to or intolerance to at least 1 bDMARD. The study objective of Period 2 (Week 24 to Week 260) is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants with RA who completed Period 1.
NCT02706873 ↗	A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate	Active, not recruiting	AbbVie	Phase 3	2016-02-23	The objectives of Period 1 were the following: - To compare the safety and efficacy of upadacitinib 7.5 mg once daily (QD) monotherapy (for participants in Japan only), 15 mg QD monotherapy, and 30 mg QD monotherapy versus weekly methotrexate monotherapy for the treatment of signs and symptoms of RA in methotrexate-naïve adults with moderately to severely active RA; - To compare the efficacy of upadacitinib 15 mg QD monotherapy and upadacitinib 30 mg QD monotherapy versus weekly methotrexate monotherapy for prevention of structural progression in methotrexate-naïve adults with moderately to severely active RA. The objective of Period 2 is to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 7.5 mg QD (for participants in Japan only), 15 mg QD, and 30 mg QD in adults with RA who have completed Period 1.
NCT02706951 ↗	A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)	Active, not recruiting	AbbVie	Phase 3	2016-03-23	The study objective of Period 1 of this study is to compare the safety and efficacy (signs and symptoms) of upadacitinib 30 mg once daily (QD) alone and upadacitinib 15 mg QD alone versus continuing MTX alone adults with moderately to severely active rheumatoid arthritis (RA) with an inadequate response to MTX. The study objective of Period 2 is to evaluate the long term safety, tolerability, and efficacy of upadacitinib 30 mg QD and 15 mg QD in adults with RA who had completed Period 1.
NCT02782663 ↗	A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease	Active, not recruiting	AbbVie	Phase 2	2016-05-18	This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).
NCT02819635 ↗	A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Active, not recruiting	AbbVie	Phase 3	2016-09-26	This study comprises three sub-studies. The objective of sub-study 1 is to characterize the dose-response, efficacy, and safety of upadacitinib compared to placebo in inducing clinical remission in order to identify the induction dose of upadacitinib for further evaluation in sub-study 2. The objective of sub-study 2 is to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission in participants. The objective of sub-study 3 is to evaluate the efficacy and safety of upadacitinib compared to placebo in achieving clinical remission in participants who had a response following induction with upadacitinib.

Clinical Trial Conditions for RINVOQ LQ

Condition Name

Condition Name for RINVOQ LQ
Intervention	Trials
Atopic Dermatitis	8
Rheumatoid Arthritis	8
Crohn's Disease	4
Ulcerative Colitis (UC)	3

Condition MeSH

Condition MeSH for RINVOQ LQ
Intervention	Trials
Arthritis	10
Eczema	9
Dermatitis, Atopic	9
Dermatitis	9

Clinical Trial Locations for RINVOQ LQ

Trials by Country

Trials by Country for RINVOQ LQ
Location	Trials
United States	742
Japan	338
China	146
Canada	117
Poland	109

Trials by US State

Trials by US State for RINVOQ LQ
Location	Trials
Ohio	32
California	31
Texas	30
Florida	30
Michigan	28

Clinical Trial Progress for RINVOQ LQ

Clinical Trial Phase

Clinical Trial Phase for RINVOQ LQ
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	1
PHASE1	1

Clinical Trial Status

Clinical Trial Status for RINVOQ LQ
Clinical Trial Phase	Trials
Active, not recruiting	15
Not yet recruiting	10
Recruiting	7

Clinical Trial Sponsors for RINVOQ LQ

Sponsor Name

Sponsor Name for RINVOQ LQ
Sponsor	Trials
AbbVie	39
Berinstein, Jeffrey	2
Ottawa Hospital Research Institute	1

Sponsor Type

Sponsor Type for RINVOQ LQ
Sponsor	Trials
Industry	44
Other	9

Last updated: April 29, 2026

RINVOQ LQ (Upadacitinib) Clinical Trials Update, Market Analysis, and Projection

What is RINVOQ LQ (upadacitinib) and how is “LQ” positioned?

RINVOQ is the brand name for upadacitinib, an oral, selective JAK1 inhibitor. Published clinical and commercial materials consistently refer to the drug as upadacitinib; “LQ” is not a standard, universally recognized regulatory or product identifier in the underlying evidence base for upadacitinib.

This market-and-trials update therefore covers RINVOQ (upadacitinib) clinical development, regimen expansions, and commercial trajectory using the core evidence and labeled indications available in public regulatory and industry sources.

---

What does the latest clinical-trials landscape show?

Approved indications that drive the clinical program

Upadacitinib is approved for multiple immune-mediated inflammatory diseases. The strongest commercial and clinical momentum sits in programs across:

• Rheumatoid arthritis (RA) (including active RA and related formulations of use)
• Psoriatic arthritis (PsA)
• Ankylosing spondylitis / axial spondyloarthritis
• Atopic dermatitis (AD)
• Ulcerative colitis (UC)
• Crohn’s disease (CD) (including later-line positioning where approved)
• Non-radiographic axial spondyloarthritis where applicable by label

The clinical strategy is consistent: expand to earlier lines, broaden across phenotypes, and deepen durability endpoints (clinical remission, endoscopic improvement where relevant, and corticosteroid-free response).

Key trial-design patterns that recur across the program

Across the RINVOQ clinical portfolio, the design pattern is:

• Phase 3 randomized comparisons versus placebo and/or active comparators
• Endpoints emphasizing rapid symptom control and durability (week- and month-based response rates)
• For IBD, inclusion of endoscopic outcomes and corticosteroid reduction as co-primary or key secondary endpoints
• For skin disease (AD), dual emphasis on itch reduction and EASI response with durability measures

What is the current state of execution (read-through from the public evidence base)?

Public regulatory and conference activity indicates that the program continues to mature in two directions:

1. Label expansion within established disease areas (positioning earlier lines and refining subpopulations)
2. Consolidation of efficacy durability (longer follow-up reads, safety exposure characterization, and treatment persistence)

Because the user request asks for “clinical trials update” for RINVOQ LQ, the most business-relevant interpretation is that the clinical program is in a scale-up and maintenance phase across multiple indications, with continued data generation to support expansions and safety surveillance, rather than a single, early-stage breakout that would change the core thesis.

---

What does the market look like for upadacitinib and RINVOQ?

Competitive set

In JAK-inhibitor and broader immunology classes, the competitive set depends on the indication:

• Other JAK inhibitors: tofacitinib, baricitinib, filgotinib (where approved), and other class entrants
• IL-17 and IL-23 biologics for PsA and axial indications
• TNF inhibitors in RA, PsA, and IBD
• IL-4/13 and broader dermatology biologics for AD
• Vedolizumab, ustekinumab, and anti-TNF for UC/CD depending on line and market segment

Market drivers

For upadacitinib, the market drivers are consistent across multiple high-value indications:

• Oral administration (patient preference, clinic logistics, and adherence)
• Fast onset in many inflammatory endpoints
• Broad label footprint spanning joint and GI disease plus AD
• Positioning across lines of therapy, including after biologic exposure where the evidence supports it
• Combination and switching patterns that align with payer frameworks for oral targeted therapy

Pricing power and payer dynamics

Oral targeted therapies often face payer scrutiny around cost-per-response and safety monitoring. The commercial balance for upadacitinib typically relies on:

• Demonstrated magnitude and speed of response
• Durability of response over longer follow-up windows
• Reduced need for corticosteroids in IBD where outcomes support it
• Clear differentiation against biologics where it shows stronger response velocity or broader subpopulation coverage

Commercial impact by indication (directional)

While exact sales figures are not supplied in the prompt, the business logic is:

• Rheumatology and dermatology generate early and repeat demand because of high prevalence and broad patient segments.
• IBD contributes meaningful revenue due to higher medical cost contexts, with oral therapy capturing patients who prefer to avoid infusion and who need alternative mechanisms when biologics underperform.

---

What is the market projection for RINVOQ upadacitinib over the next 3 to 5 years?

Projection framework

A credible projection for upadacitinib revenue growth requires three drivers:

1. Indication expansion and line-of-therapy penetration
2. Share shifts within competitive classes (JAK inhibitors and biologics)
3. Sustained persistence (treatment adherence in chronic immune disease)

Base-case outcome (directional)

Assuming:

• continued uptake in each approved category,
• label-supported switching from other immunomodulators,
• and stable safety perception with managed monitoring,

the base case for upadacitinib is mid-to-high single digit annual growth over a multi-year horizon driven by ongoing penetration and incremental indication growth, with possible step-ups around new label support or additional supportive evidence leading to payer coverage expansions.

Upside and downside cases (directional)

• Upside: faster-than-expected conversions due to strong response rates, expanded reimbursement, or additional indication approvals.
• Downside: heightened payer restrictions, competitive displacement by biologics with superior durability in specific subgroups, or a safety-related erosion in willingness to initiate.

Why this projection is structurally consistent

Upadacitinib has a mature platform across multiple immunology anchors. That structure limits single-indication risk and enables revenue smoothing through label diversity. The projection therefore reads less like a single-bet early-stage ramp and more like a multi-indication maintenance-and-expansion curve.

---

How do safety and monitoring affect adoption and long-term growth?

Long-term growth for JAK inhibitors is tied to:

• risk-benefit framing by guideline bodies and prescribers,
• monitoring workflows (labs, infection screening, cardiovascular and malignancy risk considerations where relevant),
• and safety labeling updates over time.

The business implication is that adoption stays strongest where:

• efficacy is high and rapid,
• disease burden is severe,
• clinicians already have experience using oral small molecules, and
• payer coverage aligns with outcomes data.

---

Key Competitive Questions Investors and R&D Leaders Must Answer

1. Does upadacitinib maintain share in dermatology and rheumatology while competitive entrants and biologics consolidate?
2. Do IBD outcomes and label refinements sustain switching from biologics and monoclonals?
3. Will payers shift coverage toward narrower subpopulations or outcome thresholds that compress growth?

---

Key Takeaways

• RINVOQ is upadacitinib, a JAK1 inhibitor with a broad, multi-indication clinical footprint spanning rheumatology, dermatology, and IBD.
• The clinical program is best characterized as ongoing expansion and durability evidence generation across established high-value indications rather than a single early-phase inflection.
• The market projection is structurally consistent with multi-indication penetration-driven growth, with mid-to-high single digit annual growth as a base-case direction over 3 to 5 years, subject to payer and safety dynamics.
• Adoption hinges on the balance of rapid efficacy, durability, and monitoring practicality versus competitive displacement and payer restrictions.

---

FAQs

1. What class is RINVOQ?
   RINVOQ is upadacitinib, an oral JAK1 inhibitor.

2. Which indications matter most for RINVOQ’s growth?
   Growth is typically concentrated in RA/PsA/axial spondyloarthritis, atopic dermatitis, and IBD (UC/CD).

3. What usually drives market share for upadacitinib versus biologics?
   Oral convenience, speed of symptom response, and durability of clinically meaningful endpoints.

4. How do payer policies influence projections?
   Payers often tie coverage to patient selection and outcome thresholds, affecting initiation and persistence.

5. What can change the projection up or down?
   Upside comes from expanded label/reimbursement and faster conversions; downside comes from tighter payer restrictions, subgroup access limits, or safety-related adoption drag.

---

References

[1] U.S. Food and Drug Administration (FDA). RINVOQ (upadacitinib) prescribing information.
[2] European Medicines Agency (EMA). RINVOQ (upadacitinib) product information and EPAR documents.
[3] National Institute for Health and Care Excellence (NICE). Technology appraisal guidance and related clinical evidence for JAK inhibitors (where applicable).
[4] American College of Rheumatology (ACR). Clinical guideline updates addressing JAK inhibitors and treatment selection (where applicable).
[5] ClinicalTrials.gov. Upadacitinib (RINVOQ) clinical studies records and results postings.